Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in New-onset Type 1 Diabetes
NCT02117765Phase 2Unknown
- Sponsor
- University of British Columbia
- Start
- Mar 2015
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ustekinumab in type 1 diabetes mellitus (T1D) (4 cohorts), sponsored by University of British Columbia. Primary endpoint: Primary Safety Endpoints at 12 months. Status: unknown.
02
Drugs
ustekinumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02117765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117765.